SSAA09E1 | CAS#433212-75-0

MedKoo Cat#: 555807 | Name: SSAA09E1

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SSAA09E1 is an inhibitor of SARS-CoV replication that block viral entry by three different mechanisms.

Chemical Structure

SSAA09E1

CAS#433212-75-0

Theoretical Analysis

MedKoo Cat#: 555807

Name: SSAA09E1

CAS#: 433212-75-0

Chemical Formula: C7H9N3S2

Exact Mass: 199.0238

Molecular Weight: 199.29

Elemental Analysis: C, 42.19; H, 4.55; N, 21.09; S, 32.17

Price and Availability

Size	Price	Availability
5mg	USD 265.00	2 Weeks
10mg	USD 450.00	2 Weeks
25mg	USD 750.00	2 Weeks
50mg	USD 1,250.00	2 Weeks
100mg	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SSAA09E1; SSAA09 E1; SSAA09-E1;

IUPAC/Chemical Name

[(Z)-1-Thiophen-2-ylethylideneamino]thiourea

InChi Key

PJVHAJJEMJNPHN-UITAMQMPSA-N

InChi Code

InChI=1S/C7H9N3S2/c1-5(9-10-7(8)11)6-3-2-4-12-6/h2-4H,1H3,(H3,8,10,11)/b9-5-

SMILES Code

S=C(N)N/N=C(C1=CC=CS1)/C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SSAA09E1 reduces infection of HEK293T cells transiently transfected with angiotensin-converting enzyme 2 (ACE2) by an HIV-based virus system pseudotyped with SARS-CoV spike glycoprotein (EC50 = 6.7 μM). SSAA09E1 also inhibits the proteolytic activity of cathepsin L (IC50 = 5.33 µM) but not cathepsin B when used at a concentration of 20 µM.

In vitro activity:

SSAA09E1 blocked the activity of the host protease cathepsin L, which is necessary for the processing of the SARS-CoV surface glycoprotein during viral entry. This inhibition occurs at a later stage in the viral entry process. Reference: J Virol. 2013 Jul;87(14):8017-28. https://pubmed.ncbi.nlm.nih.gov/23678171/

In vivo activity:

To be determined

Preparing Stock Solutions

The following data is based on the product molecular weight 199.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Adedeji AO, Severson W, Jonsson C, Singh K, Weiss SR, Sarafianos SG. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013 Jul;87(14):8017-28. doi: 10.1128/JVI.00998-13. Epub 2013 May 15. PMID: 23678171; PMCID: PMC3700180.

In vitro protocol:

In vivo protocol:

To be determined

Adedeji AO, Severson W, Jonsson C, Singh K, Weiss SR, Sarafianos SG. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013 Jul;87(14):8017-28. doi: 10.1128/JVI.00998-13. Epub 2013 May 15. PMID: 23678171; PMCID: PMC3700180.